Viral Conjunctivitis Drugs Market, By Drug Class (Antibiotics, Artificial tears, Decongestants, Anti-histamines, NSAIDS, Anti-Viral drugs, Others (Steroids, etc.)), By Virus Type (Adenovirus, Enterovirus, Others (Herpes Simplex Virus (HSV), etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023

Code : CMI1281

Pages :214

Formats :

Excel and PDF

Industry : Pharmaceutical

Viral Conjunctivitis Drugs MarketSize and Trends

The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).

The rising number of product launches by the key market players in the global viral conjunctivitis drugs market is expected to propel over the forecast period.

Figure 1. Global Viral Conjunctivitis Drugs Market Share (%), By Drug Class, 2023

Global Viral Conjunctivitis Drugs Market– Drivers

Increasing Prevalence of Viral Conjunctivitis:
Rising Healthcare Expenditure:

Figure 2. Global Viral Conjunctivitis Drugs Market Share (%), By Region, 2023

Global Viral Conjunctivitis Drugs Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global viral conjunctivitis drugs market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023.

Global Viral Conjunctivitis Drugs Market- Cross Sectional Analysis:

Global Viral Conjunctivitis Drugs Market Segmentation:

Global Viral Conjunctivitis Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

Global Viral Conjunctivitis Drugs Market - Key Players

Major players operating in the global viral conjunctivitis drugs market include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.

Global Viral Conjunctivitis Drugs Market: Key Trend